Teva’s Ajovy (fremanezumab-vfrm) has demonstrated potential as the first calcitonin gene-related peptide (CGRP) antagonist treatment option for preventing episodic migraines in paediatric and adult patients.
Teva’s Ajovy (fremanezumab-vfrm) has demonstrated potential as the first calcitonin gene-related peptide (CGRP) antagonist treatment option for preventing episodic migraines in paediatric and adult patients.